Hepatitis C virus infection: Its role in chronic liver diseases

Abstract

In order to find out the infectious rate of hepatitis C viris (HCV) among chronic liver diseases, we investigated antibodies against hepatitis C virus and HCVRNA by method of ELISA, R1BA and RT-PCR in 410 patients with chronic liver disease. The prevalence of HCV infection was found to be 4%. Whereas the positive rate of HBsAg and HBV-DNA of these cases was 69% and 58%, respectively. There is no statistical significance between HCV infectious rate of patients with positive and negative HBsAg. The relative low infectious rate of HCV infection among chronic hepatic diseases indicates that HBV infection plays a more important role in causing chronic hepatitis than that of HCV. Thus, special emphasis should be paid to the preventive and therapeutic measures against hepatitis B in China.

Keywords

chronic liver disease / hepatitis C virus / HCVRNA / RT-PCR

References

[1] FeinstoneS M, KapikanA Z, PurcellR H, et al.. Transfusionassociated hepatitis not due to viral heptitis A or B. N Engl J Med, 1975, 292: 767-770

[2] AlterH J, HollandP V, MorrowA G, et al.. Clinical and serological analysis of transfusion-associated hepatitis. Lancet, 1975, 2: 838-841

[3] AlterH J, PurcellR H, ShihJ W. Detection of antibody to hepatitis c virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis. N Engl J Med, 1989, 321: 1494-1500

[4] EstebanJ I, GonzalesA, Heranandes JM, et al.. Evaluation of antibodies to hepatitis C virus in a study of transfusion-associated hepatitis. N Engl J Med, 1990, 323: 1107-1112

[5] KuoG, ChooQ-L, AlterH, et al.. An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science, 1989, 2: 297-298

[6] Van Der PoelC L, ReesinkH W, LelieP N, et al.. Anti-hepatitis C antibodies and non-A, non-B posttransfusion hepatitis in the Netherlands. Lancet, 1989, 2: 297-298

[7] MiyamuraT, AaitoI, KatayamaT, et al.. Detection of antibody against antigen expressed by molecularly cloned hepatitis C virus cDNA: Application to diagnosis and blood screening for posttransfusion hepatitis. Proc Natl Acad Sci USA, 1990, 87: 983-987

[8] ChenD S, KuoG C, SungJ L, et al.. HCV infection in an area hyperendemic for hepatitis and chronic liver disease: The Taiwan experience. J Infec Disea, 1990, 162: 817-822

[9] FattovichG, TaggerA, BrolloL, et al.. HCV infection in chronic hepatitis B virus carriers. J Infec Disea, 1991, 163: 400-402

[10] HanssonB G, MoestupT, WidellA, et al.. Infection with delta agent in Sweden: Introduction of a new hepatitis agent. J Infec Disea, 1982, 146: 472-478

[11] ChomczynskiP, SacchiN. Single-step method of RNA isolation by acid guanidinum thiocyanate-phenol-chloroform extration. Analytic Biochem, 1987, 162: 156-159

[12] WidellA, ManssonA S, SundstromG, et al.. Hepatitis C virus RNA in blood donor sera detected by the polymerase chain reaction: Comparison with supplementary hepatitis C antibody assays. J Med Virol, 1991, 35(4): 253-253

[13] McFarlaneI G, SmithH M, JohansonP J, et al.. HCV antibody in chronic active hepatitis: pathogenetic factor or false positive result?. Lancet, 1990, 335: 754-757

[14] WongD C, DiwanA R, RosenL, et al.. Non-specificity of anti-HCV test for seroepidemiological analysis. Lancet, 1990, 336: 750-751